SynthesisBMC gastroenterology2025
Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting Prolonged Length of Stay in Acute Pancreatitis: Comparison of the CRP-to-Albumin Ratio with Other Inflammatory and Immunoutritional Indices.Metabolites · 2026Article
- Dynamic Assessment of Modified EASIX (m-EASIX) at 48 Hours Predicts Adverse Outcomes in Acute Pancreatitis: A Propensity Score-Matched Study.Medicina (Kaunas, Lithuania) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis (AP) is an inflammatory disease with a heterogeneous clinical course, ranging from mild symptoms to life-threatening complications. The platelet-to-lymphocyte ratio (PLR), an easily accessible inflammatory biomarker, has shown prognostic value in other conditions but has been understudied in AP. This review aimed to systematically evaluate the association between PLR and AP severity.
methodsA PRISMA-guided systematic review and meta-analysis was conducted, searching PubMed, Web of Science, Scopus, and WHO-VHL databases (earliest records to March 2025). Observational studies reporting PLR and AP severity were included. Pooled standardized mean differences (SMDs) were calculated using a random-effects model.
resultsAmong 20 included studies encompassing 5,920 patients, PLR was significantly higher in severe acute pancreatitis (SAP) versus non-SAP (SMD = 1.137, 95% CI: 0.752–1.702, P < .001). Subgroup analysis by SAP definition revealed significant differences (p = .011). In studies using the Revised Atlanta classification, PLR was markedly higher in SAP patients (SMD = 1.479, 95% CI: 0.729 to 2.231). The Egger’s regression test and funnel plot indicated no significant publication bias (p = .105) and the sensitivity analysis confirmed robustness of the findings.
conclusionPLR may serve as a low-cost biomarker for AP severity stratification, with higher levels indicating severe disease and poor outcomes. Its integration into clinical practice could enhance early risk assessment, particularly in resource-limited settings. Prospective studies are needed to validate optimal cutoff values and refine its prognostic utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.